Goldman Sachs raised the firm’s price target on Regeneron (REGN) to $914 from $807 and keeps a Buy rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Anavex appoints Wolfgang Liedtke as SVP, global head of neurologyRegeneron
- Midday Fly By: Warner Bros. urges holders to reject Paramount bid
- 3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026
- Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls
- Regeneron price target raised to $900 from $700 at Citi